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The treatment of rheumatic diseases has been the focus of many clinical studies aiming to achieve the best
combination of drugs for symptom reduction. Although improved understanding of the pathophysiology of
rheumatic diseases has led to the identification of effective therapeutic strategies, its cure remains unknown.
Biological agents are a breakthrough in the treatment of these diseases. They proved to be more effective than the
other conventional therapies in refractory inflammatory rheumatic diseases. Among them, tumor necrosis factor
inhibitors are widely used, namely Etanercept, Infliximab, or Adalimumab, alone or in combination with
disease-modifying antirheumatic drugs. Nevertheless, severe adverse effects have been detected in patients with
history of recurrent infections, including cardiac failure or malignancy. Currently, most of the available therapies
for rheumatic diseases do not have sufficient tissue specificity. Consequently, high drug doses must be ad-
ministrated systemically, leading to adverse side effects associated with its possible toxicity. Drug delivery
systems, by its targeted nature, are excellent solutions to overcome this problem. In this review, we will describe
the state-of-the-art in clinical studies on the treatment of rheumatic diseases, emphasizing the use of biological
agents and target drug delivery systems. Some alternative novel strategies of regenerative medicine and its
implications for rheumatic diseases will also be discussed.
Rheumatic Diseases and Categories of Treatments
There are over 100 types of rheumatic diseases, arthri-tis, and related conditions. Examples of inflammatory
rheumatic diseases include rheumatoid arthritis (RA), an-
kylosing spondylitis (AS), psoriatic arthritis (PsA), systemic
lupus erythematosus, juvenile idiopathic arthritis ( JIA), and
osteoarthritis (OA).1,2 These diseases affect people of all ages
and genders, and until today, its causes remain unknown, as
well as its cure. According to the Center for Disease Control
and Prevention, over 46 million people in the United States
have some form of arthritis or chronic joint symptom.
There are several treatments aiming at easing pain, in-
flammation, and joint damage progression. The plans of
treatment often include short-term and long-term relieve
approaches. Short-term treatments involve pain relievers
such as nonsteroidal anti-inflammatory drugs, joint immo-
bilization periods, massage, and heat or cold applications.
Long-term management includes medication, weight reduc-
tion plans, exercise, or surgery. Conventional drug treat-
ment for rheumatic inflammatory diseases combines basically
a symptom-modifying antirheumatic drug with disease-
modifying antirheumatic drugs (DMARDs). The combination
of symptom-modifying antirheumatic drugs with DMARDs
can slow inflammation and, in some cases, modify the pro-
gression of the disease.3 In this review, we will focus on long-
term medication with DMARDs and biological agents.
Additionally, we will discuss novel possibilities based on cell
therapy and tissue engineering for the treatment of rheumatic
diseases.
Biological Agents in the Treatment
of Rheumatic Diseases
Advances in biotechnology have led to the development
of agents that therapeutically target specific components of
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the deregulated immune system, known as ‘‘biological
agents.’’4,5 Among them, tumor necrosis factor a (TNFa) and
interleukin-1a and b have a significant role in the patho-
genesis of rheumatic diseases.6,7 Biological agents are par-
tially or fully humanized recombinant proteins that target
different pathways of the immune response. Further infor-
mation on the safety and efficacy of TNF blockers can be
obtained, for example, in Ref.8 The most used biological
agents for the treatment of rheumatic diseases and their
characteristics and secondary effects are also presented in
Table 1.
Among the different biological agents used in clinical
practice, TNFa inhibitors have proven to be highly effective
in the treatment of advanced rheumatic diseases, such as
RA, AS, PsA, or JIA,1,4,6,9,10 reducing their symptoms, im-
proving the physical function of joints, and inhibiting
joint damage progression.7 The cost of TNFa inhibitors is
one of the main limitations associated with this therapy:
they are considerably more expensive than the traditional
DMARDs. Considering the high cost of these drugs, several
strategies of combination of these agents with DMARDs are
being increasingly studied,5,8,11 as is explained in the next
section.
Long-Term Efficacy of Biological Agents and
Their Impact on the Patients’ Quality of Life
Various studies showed the efficacy of biological agents
and most of the patients respond well to the treatments using
these medications alone or in combination with others
DMARDs. According to the guidelines of the British Society
of Rheumatology, the treatment of active AS with TNF
blockers leads to a sustained response for over 2 years, most
patients showing tolerance to these drugs.12 Another study
showed a rapid clinical improvement of patients with AS
(as early as 2 weeks) after the onset of anti-TNF therapy.13
Chronic therapy with Adalimumab improved measures of
fatigue and health-related quality of life in patients with
longstanding RA diagnosis. This effect was maintained for a
mean of 1.6 years in all applied measures.14 Subcutaneous
administration of Etanercept was effective and generally well
tolerated in large-scale clinical trials in patients with RA.15
A therapy combining methotrexate (MTX) with Infliximab,
Etanercept, or Adalimumab in RA was generally superior to
monotherapy in reducing the disease activity and joint dam-
age, as well as improving health-related quality of life.15,16
Before initiating the therapy with TNF inhibitors, some
contraindications must be considered by physicians to min-
imize the risks including active infections, history of recur-
rent or chronic infections, cardiac failure, or malignancy.8,17
The blockade of a critical proinflammatory cytokine in pa-
tients already taking other anti-inflammatory agents may
trigger severe infections. The most severe secondary effect of
anti-TNFa was tuberculosis.8,18–20 The development of anti-
bodies against the TNFa inhibitors is another possible
problem,5,17,18 as well as lupus-like syndrome.9 When the
first TNF antagonist fails, perhaps the best alternative is to
switch to a different type of biological agent such as Aba-
tacept or Rituximab and, in the case of adverse event to a
previous treatment, to another TNF inhibitor.21
To reach effective drug concentrations in the affected joint
tissues, high doses of the therapeutic agent must be admin-
istered systemically, which may lead to significant adverse
systemic and extra-articular side effects. Currently, most of
the available therapies for rheumatic diseases do not have
tissue specificity and have a ubiquitous distribution of mo-
lecular targets. Reduction in drug doses may attenuate tox-
icity, being a plausible solution, but may lead to reduced
therapeutic efficacy. To overcome these limitations, targeted
drug delivery systems may provide excellent solutions by
incorporating the available antirheumatic drugs and releas-
ing them at the target sites.22
Novel Approaches for Targeted Delivery
of Antirheumatic Drugs
Drug delivery systems have been developed in several
emerging research fields such as tissue engineering and re-
generative medicine, as a method to address the problems
associated with conventional drugs and improve their phar-
Table 1. Biological Agents Used in Clinical Practice for the Management of Rheumatic Diseases
Trade name Type
Mechanism
of action Application Secondary effects
Abatacept CTLA4 Ig Costimulation
inhibitor
RA; CV; SLE Serious infection
Adalimumab Anti-TNFa TNF inhibitor RA; AS; PsA Infections, fatal sepsis,
demyelinating events
Anakinra IL-1ra IL1 inhibitor RA; AS Severe infection
Etanercept TNF-a R=Fc
fusion protein
TNF inhibitor RA; AS; SA; PsA; JIA Infections, bronchitis
Infliximab Anti-TNFa TNF inhibitor RA; AS; SA; PsA; DM=PM Tuberculosis, lupus-like
syndrome, heart failure,
pancreatitis, liver failure
Rituximab Anti-CD20 mAb B-cell depletion RA; CV; SLE Cardiac arrest, infections,
immune toxicity
Table adapted from Konttinen et al.3 and Diaz-Borjon et al.8
RA, rheumatoid arthritis; CV, cryoglobulinemic vasculitis; SLE, systemic lupus erythematosus; AS, ankylosing spondylitis; PsA, psoriatic
arthritis; IL, interleukin; SA, secondary amyloidosis; JIA, juvenile idiopathic arthritis; DM, dermatomyositis; PM, polymyositis.
332 ALVES DA SILVA ET AL.
macological properties. The means by which a drug is re-
leased may have a considerable effect on its efficacy and
therapeutics. Drug delivery systems have been designed
using different polymers of either synthetic or natural origin.
There is a great potential to further develop these systems,
because they allow the manipulation of the kinetics of
release, by playing with specific parameters such as poly-
mer type, molecular weight, or processing method.23,24 In the
development of synthetic polymers for drug delivery, both
the polymer and the bioactive agent are generally mixed and
processed into a suitable carrier. As the bioactive agent is
deeply inside the polymer, its release will also depend on the
kinetics of biodegradation of the polymer.25,26 The previous
systems depend mostly on diffusion and degradation rates,
whereas several new systems depend more on the status of
the regenerative area to release bioactive agents. For exam-
ple, hydrogels have been developed to respond to environ-
mental changes, such as compressive stimulation of the
matrix, providing mechanically controlled release of bioac-
tive agents or specific growth factors.25
To achieve a better control over drug release, several
technologies have been developed. Most of these procedures
are based on a combination of bioactive agents and bioma-
terials by bonding. Many examples of these strategies have
been reported in recent literature.27 Materials used in these
processes include poly(d,l-lactide-co-glycolide) (PLGA),28
polycaprolactone,29 chitosan,30 or starch.31
Intra-articular injection (IA) of drug delivery systems en-
ables the incorporated drug to be released in the proximity of
the targeted area. IA of drugs presents the advantage of re-
ducing the amount of drug required at the injured site and
minimizing the exposure to the drugs to unintended sites.32
Nevertheless, one of the main challenges for IA formulation
development is to achieve a long-lasting release of the
drug.33 Most of the new chemical drugs used for therapeutic
purposes are not soluble in water, which is a major adverse
factor conditioning its effectiveness.34 Therefore, novel strat-
egies of drug delivery in situ are being investigated and de-
veloped, such as micro- or nanoparticles and liposomes.
Microparticulate systems showed to be very promising for
controlled release applications,23,33 namely as carriers of dif-
ferentiation agents such as dexamethanone.29 Indomethacin-
biodegradable and biocompatible polymer conjugates were
developed to target the intra-articular region. Namely, PLGA
microspheres incorporating a polyethylene glycol derivative
(Labrafil) was used to prolong indomethacin release in the
joint for up to 19 days.28 A different drug carrier comprises
paclitaxel-loaded microspheres of poly(l-lactic acid) showing
a sustained release over 30 days and an efficient intra-articular
reduction of inflammation conditions (i.e., joint swelling, cell
infiltration, proteoglycan loss, chondrocyte necrosis) in rabbit
models of antigen-induced arthritis.35 Besides these drug
carriers, there has been relatively few experiments on the
development of other carriers to deliver antirheumatic drugs,
namely DMARDs, such as albumin-MTX conjugate tested in
an arthritic rodent model36 or MTX-loaded PLLA micro-
spheres injected intra-articularly in healthy rabbits.37 Despite
the limitations of systemic administration of antirheumatic
drugs, IA of DMARDs has not been an area of much interest
or investigation because these drugs were not expected to
remain in the joints.38
Polymeric nanoparticles were proposed for controlled re-
lease of different bioactive agents.28,29,39–41 These carriers
were extensively studied for targeting articular cartilage
diseases such as OA. Nanoparticles for this type of applica-
tion generally contain a specific cartilage-binding moiety.23
Moreover, to reach competent carrier penetration into the
cartilage, the carrier size may play an essential role. This
aspect was demonstrated by Rothenfluh et al.42 for nano-
particles coated with collagen II-binding peptide. In a recent
study, folic acid was coupled to the surface amino groups of
poly(amidoamine) dendrimers and loaded with indometha-
cin (a nonsteroidal anti-inflammatory drug used for the man-
agement of RA, OA, and acute gout).43 Results demonstrated
that folate–dendrimer conjugates are a suitable vehicle for
site-specific delivery of an antiarthritic drug to active inflam-
mation sites, namely the inflamed paw of arthritic rats. Our
group has been studying targeted drug delivery systems
for cartilage and bone. In a recent study, poly(amidoamine)
dendrimers conjugated with carboxymethylchitosan nano-
particles proved to be very interesting for mesenchymal stem
cell (MSC) studies and application in regenerative medicine.
In this study, the materials were able to induce osteogenic
differentiation of rat MSCs in vitro.40
Liposomes are another type of carrier used for drug de-
livery applications. Research on this carrier has mainly been
focused on increasing its retention as a function of particle
size and biocompability.23,33
Although some forms of arthritis may be treated by the
intra-articular administration of drugs such as glucocorti-
coids, this approach may be limited by the rapid clearance of
the drugs from the synovial space, resulting in only transient
efficacy. The use of polyethylene glycol liposomes44 and
PLGA nanospheres45 as drug carriers for the localized deliv-
ery of glucocorticoids into the synovial space has been pro-
posed. Polymeric carriers were preferred, because a proper
design of linkage between the drug and the polymer back-
bone allows a finely controlled kinetics of local drug release.
Conversely, accumulation of the liposomes in liver and
spleen is well documented. Recently, Wang et al.46 developed
a novel pH-sensitive drug delivery system of dexametha-
sone based on an N-(2-hydroxypropyl)methacrylamide co-
polymer and showed that the delivery system specifically
accumulates in inflamed joints of an adjuvant-induced ar-
thritis rat model.
Local application of anti-inflammatory and osteo- and
chondroprotective agents by means of cellular gene therapy
is an attractive alternative for cartilage repair, because it may
provide long-term expression of the therapeutic agents and
minimize systemic adverse effects.47,48 This treatment strat-
egy is based on the use of genetically engineered cells that
have the ability to migrate into the sites of active autoim-
mune inflammation to express and deliver therapeutic gene
products. There are many strategies used for the delivery of
exogenous cDNAs for the treatment of cartilage diseases. All
these require an efficiently delivery of the cDNA of interest
to the target cells to enable a sustained and long-lasting
transgene expression to trigger the desired biological re-
sponse.49 There are two ways for IA gene delivery: direct or
indirect. The direct way consists of an in vivo approach, ap-
plying the vector directly in the joint.49 The indirect method
is based ex vivo and entails genetically modified cells, which
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are further transplanted into the body. In vivo approaches
have the advantage of being less invasive than the ex vivo
ones.50 They are also more economic because they do not
require cell manipulation. Nevertheless, the transfected cells
are injected directly into the body, increasing the risks for the
patients.49,51 Ex vivo approaches are more invasive and ex-
pensive, but they allow for a better control of the transduced
cells and also their testing for safety before the trans-
plant.49,51 More details about the specific aspects of these
technologies can be obtained from Refs.43–45
The administration of targeted signaling molecules and
growth factors is another adequate way to manipulate cell
behavior. The use of proper growth factors to direct stem cells
into the chondrogenic lineage can lead to the formation of a
cartilage-like tissue by transplanted cells.52–56 Cell-mediated
gene transfer allows the transplantation within the tissue of
therapeutically relevant cell populations previously directed
into specific cell lineages with differentiation factors.
There are three types of primary candidate cell types used
to target genetic modifications for the treatment of damaged
articular cartilage: synovial cells,55–57 chondrocytes,52,53,58
and MSCs.54,59–61 There are several genes involved in carti-
lage development and maintenance. These genes have been
broadly studied as target genes for modification of cells in-
volved in the repair of articular cartilage. Transduction of
chondrocytes has been performed of several genes involved
in its signaling pathways and extracellular matrix, such as
the transcription factor sry (sex-determining region Y)-Box9
(Sox9),62,63 bone morphogenic protein-2 (BMP-2),52,53,55
transforming growth factor (TGF)-b1,64 BMP-2,53,64 and
insuline-like growth factor (IGF-1).64 MSCs have also been
transduced with several genes to enhance their chondrogenic
differentiation, such as BMP-4,65,66 TGF-b1,67 or TGF-b3.68
For ex vivo gene transfer approaches, different vectors
have been developed, namely viral and nonviral. Adenoviral
vectors have been considered to be most efficient and capa-
ble of infecting a wide variety of cell types.50 Nonviral gene
transfer is considered to be less efficient than the viral
vectors, but allow large-scale preparations, with low costs,
and there is no risk of generating replication-competent
pathogenic viruses. Nonviral vectors are also mainly non-
immunogenic.69
A gene delivery for many applications in vivo can be
achieved by complexing plasmid DNA with chemical agents
such as polymers70 and liposomes.69 Another approach for
controlled gene delivery for tissue engineering purposes is
loading biodegradable materials with DNA molecules.71–73
Collagen-based scaffolds have been investigated as carriers
for plasmid DNA.71,73 For example, Capito and Spector have
demonstrated that collagen-based scaffolds can serve as
nonviral gene delivery vehicles for IGF-1, providing a locally
sustained therapeutic level of IGF-1, which enhanced carti-
lage formation.71
Several gene therapy approaches have been established
in preclinical animal models, namely a murine model of
collagen-induced arthritis and an immunodeficient mouse
model of RA.47,48 The latest model enables exploring new
gene therapy approaches from pure animal model research
being one step closer to the human RA patients by using
human ‘‘vehicle cells.’’ At the moment, some human clin-
ical phase I trials of arthritis gene therapy are being per-
formed.74
Alternative Strategies for Regenerative Medicine
of Rheumatic Diseases
Over the last few years, immunotherapy targeting anti-
inflammatory cytokines aims at delaying the progress of the
degeneration of the joint cartilage and bone loss, but not its
regeneration. To address the need for improved therapies to
promote cartilage and bone repair or regeneration, a number
of novel tissue engineering approaches have been developed
for the treatment of rheumatic diseases.75 Several synthetic
and natural materials were already proposed for controlled
release in the context of tissue regeneration,76–79 as described
in the previous section. Starch-based materials and com-
posites are among those biomaterials and have shown to
induce lower inflammatory cytokines, compared with
poly(l-lactide).76 Several studies show the efficiency and the
utility of starch in different systems for drug delivery, such
as fibers,80 microspheres,81 or nanoparticles.82 Starch-based
microparticles were developed in our group for drug deliv-
ery systems83 and showed to be viable as carriers for the
incorporation and release of corticosteroids77 and growth
factors29,31,84 and as supports for cells.79
Autologous chondrocyte transplantation (ACT) in human
cartilage defects has shown promising results in early clinical
studies, but little difference in the efficacy was observed in
comparison to surgical procedures such as mosaicoplasty.85
Further, ACT has been associated with significant donor-site
morbidity and the initiation of osteoarthritic changes in the
joint due simply to harvest of the donor cartilage, indicating
the need for alternative cell sources for the tissue-engineered
repair of cartilage.86 Matrix-assisted autologous chondro-
cyte implantation, on the other hand, uses biomaterials to
sustain the transplant. Different resorbable transplants were
tested in the clinic and presents promising results.87 For
cartilage repair, chondrocyte-seeded 3D biomaterials already
reached the clinic.88 The biomaterial ensures initial mechan-
ical stability and an appropriated 3D environment for cell
proliferation and differentiation. Thus, biomaterials avoid
the need to use chondral sutures, one of the major draw-
backs of the ACT, and because of the possibility of stable
transplant fixation, a healthy cartilage surrounding is not
required.75
MSCs are of special interest as they could be isolated from
many adult tissue types and are characterized by their ability
to undergo extensive self-renewal in vitro and to assume
multilineage differentiation.89 Unlike chondrocytes, these
cells are available in a unlimited fashion and do not lose their
phenotype during expansion.90 Moreover, MSCs are less
immunogenic than chondrocytes, avoiding allogenic rejec-
tion, and have been tested successfully in animal models
of arthritis.91 Importantly, they secrete or can be genetically
manipulated to secrete immunosuppressive factors and ther-
apeutic agents that target inflammatory tissues. The chal-
lenge in using MSCs as a cell source for articular cartilage
tissue engineering is therefore to maintain the MSC-derived
chondrocytes in the prehypertrophic state and prevent them
from undergoing terminal differentiation as seen in the
growth plate.92 MSCs have been used in OA therapy by
means of delivery to the site defect, either by direct IA or
using a scaffold or matrix to support the cells.90 Recently, it
was demonstrated the potential of gelatin microspheres
containing TGF-b3 to induce chondrogenic differentiation of
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MSCs isolated from bone marrow of New Zealand rabbits.93
Nevertheless, a study that investigated the chondrogenesis
of bone marrow-derived MSCs in aggregate cultures fol-
lowing genetic modification with adenoviral vectors en-
coding TGF-b1 and BMP-2 demonstrated that transgene
expression was highly transient, showing a marked decrease
after 7 days.60 More recently, Sun et al. showed that adeno-
associated virus effectively transduced human bone marrow-
derived MSCs.73
Some nanofibrous polymeric membranes were successfully
developed in our laboratory using the electrospinning tech-
nology. They were used for production of cartilage tissue-
engineered tissue. It was generated effectively and showed to
have the potential for the treatment of cartilage degenerative
diseases. These membranes are currently under patent process
(WO 2006=138552 A2). In a recent study using bovine artic-
ular chondrocytes, starch-polycaprolactone (SPCL) and poly-
caprolactone nanofiber meshes were shown to be suitable as a
support for cartilaginous extracellular matrix production.94
Hydrogels have also been described as good matrices to
support cells, particularly chondrocytes, as stated previ-
ously. A gene-activated chitosan–gelatin matrix was devel-
oped by Guo et al. in 2006,70 for cartilage defect restoration.
The referred matrixes were capable of releasing TGF-b1 in a
controlled fashion and promoted chondrocyte proliferation.
Chitosan-based scaffolds were also successfully used in a
cartilage defect model in sheep.95 A biodegradable hydrogel
composite of oligo(poly(ethylene glycol) fumarate) with
encapsulated rabbit marrow MSCs and gelatin micropar-
ticles loaded with TGF-b1 was tested for cartilage tissue
engineering. It was demonstrated that the encapsulated
rabbit MSCs differentiated into chondrocyte-like cells, sug-
gesting the potential of this strategy for localized delivery of
stem cells and bioactive molecules.96 Another study using
rabbit MSCs evaluated the efficacy of IA of chondroitin
sulphate carried by a hydrogel in the treatment of chondral
defects in adult rabbit models. The histological and biome-
chanical properties of the repaired cartilage were improved,
which suggests that this may be an effective treatment for
cartilage injury.97 Recently, the potential of a composite
hydrogel was tested with bovine articular chondrocytes.
Cells were encapsulated in the hydrogel and the results
showed that they survived and retained their chondrocytic
morphology.98
We have been developing several natural-based hydrogels
using, for example, starch,99 gellan gum,100 or chitosan,101
the last two being specific for cartilage regeneration. More
recently, a novel injectable carrageenan=fibrin=hyaluronic
acid-based hydrogel with in situ gelling properties was used
for cartilage tissue engineering purposes.102 When seeded
with human articular chondrocytes, this injectable hydrogel
was able to regenerate and repair a lesion in bovine articular
cartilage, showing great potential as a novel delivery system
for cartilage tissue engineering.102
However, an open question of cell-based therapies is the
unknown influence of the inflammatory conditions observed
in the joint of patients with OA or inflammatory arthritis on
cell suspensions or 3D constructs. To overcome this inflam-
matory condition, the systemic or local anti-inflammatory
drugs and biological agents can be applied combined or
separately, released in a controlled manner from the implant
itself, or secreted by genetically manipulated MSCs.
The future generation of regenerative medicine for rheu-
matic diseases is focused on in situ therapies. This strategy
consists in cell-free chondroinductive scaffold implantation
combined with chemotactic molecules that allow the re-
cruitment of joint-inherent and surrounding cells to trau-
matic or arthritic diseased joints, and their subsequent
contribution for growth and differentiation in factor-guided
joint repair.103 It is believed that the biological agents and
anti-inflammatory drugs will complement the in situ therapy
of chronic joint diseases, enhancing joint tissue regeneration
and preventing the degradation of the native and neotissues
formed.75
Conclusions
The treatment of rheumatic diseases has been focused on
the achievement of the best drug combination for symptom
reduction. Although improved understanding of the patho-
physiology of rheumatic diseases has led to the identification
of effective therapeutic strategies, its cure remains unknown.
Even so, biological agents proved to be more effective than
other conventional therapies in refractory inflammatory
rheumatic diseases. Among them, TNF inhibitors are widely
used, namely Etanercept, Infliximab, or Adalimumab, alone
or in combination with DMARDs.
Local drug delivery systems are promising solutions re-
garding tissue specificity. They allow a targeted delivery of
the drug at the damage tissue, reducing side effects associ-
ated with its possible toxicity. Alternative strategies for re-
generative medicine are based on a number of novel tissue
engineering approaches, which have been developed for the
treatment of rheumatic diseases. Recently, natural-based
polymeric scaffolds have showed promising results for bone
or cartilage regeneration. These scaffolds could be improved
in a drug delivery system to perform an ‘‘on-site’’ treatment.
Further optimization will be needed, but this is a step for-
ward in joining the two concepts of therapies in one major
strategy for rheumatic disease treatment.
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